Minimal learning curve for minimally invasive aortic valve replacement.


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
03 Jun 2024
Historique:
medline: 4 6 2024
pubmed: 4 6 2024
entrez: 3 6 2024
Statut: aheadofprint

Résumé

Minimally invasive aortic valve replacement (MiAVR) is an established technique for surgical aortic valve replacement (AVR). Although MiAVR was first described in 1993 and has shown good results compared to full sternotomy AVR (FSAVR) only a minority of patients undergo MiAVR. We recently started using MiAVR via an upper hemisternotomy. We aimed to examine the early results of our initial experience with this technique. We compared 55 MiAVR to a historical cohort of 142 isolated FSAVR (12.2016-12.2022). The primary outcome was in-hospital mortality. Secondary outcomes included cardiopulmonary bypass (CPB) and cross clamp times, blood product intake, in hospital morbidity, and length of ICU and hospital stay. There was no significant difference in preoperative characteristics, including age, laboratory values and co-morbidities. There was no significant difference between the groups regarding in-hospital mortality (FSAVR 3.52% vs MiAVR 1.82%). There was no significant difference in CPB time (FSAVR 103.5 min [IQR 82-119.5] vs MiAVR 107 min [92.5-120]), aortic cross-clamp time (FSAVR 81 min [66-92] vs MiAVR 90 min [73-99]), and valve size (FSAVR 23 [21-25] vs MiAVR 23 [21-25]). The incidence of intraoperative blood products transfusion was significantly lower in the MiAVR group (10.91%) compared to the FSAVR group (25.35%, P=0.03). Our findings further establish the possibility of reducing invasiveness of AVR without compromising patient safety and clinical outcomes. This is true even in the learning curve period and without requiring any significant change in the operative technique and dedicated equipment.

Sections du résumé

BACKGROUND BACKGROUND
Minimally invasive aortic valve replacement (MiAVR) is an established technique for surgical aortic valve replacement (AVR). Although MiAVR was first described in 1993 and has shown good results compared to full sternotomy AVR (FSAVR) only a minority of patients undergo MiAVR. We recently started using MiAVR via an upper hemisternotomy. We aimed to examine the early results of our initial experience with this technique.
METHODS METHODS
We compared 55 MiAVR to a historical cohort of 142 isolated FSAVR (12.2016-12.2022). The primary outcome was in-hospital mortality. Secondary outcomes included cardiopulmonary bypass (CPB) and cross clamp times, blood product intake, in hospital morbidity, and length of ICU and hospital stay.
RESULTS RESULTS
There was no significant difference in preoperative characteristics, including age, laboratory values and co-morbidities. There was no significant difference between the groups regarding in-hospital mortality (FSAVR 3.52% vs MiAVR 1.82%). There was no significant difference in CPB time (FSAVR 103.5 min [IQR 82-119.5] vs MiAVR 107 min [92.5-120]), aortic cross-clamp time (FSAVR 81 min [66-92] vs MiAVR 90 min [73-99]), and valve size (FSAVR 23 [21-25] vs MiAVR 23 [21-25]). The incidence of intraoperative blood products transfusion was significantly lower in the MiAVR group (10.91%) compared to the FSAVR group (25.35%, P=0.03).
CONCLUSIONS CONCLUSIONS
Our findings further establish the possibility of reducing invasiveness of AVR without compromising patient safety and clinical outcomes. This is true even in the learning curve period and without requiring any significant change in the operative technique and dedicated equipment.

Identifiants

pubmed: 38830605
doi: 10.1055/a-2337-1978
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Dror B Leviner (DB)

cardiothoracic surgery, Carmel Medical Center Cardiovascular Center, Haifa, Israel.

Tom Ronai (T)

cardiothoracic surgery, Carmel Medical Center Cardiovascular Center, Haifa, Israel.

Dana Abraham (D)

Technion Israel Institute of Technology, Haifa, Israel.

Hadar Eliad (H)

cardiothoracic surgery, Carmel Medical Center Cardiovascular Center, Haifa, Israel.

Naama Schwartz (N)

Research Authority, Carmel Medical Center, Haifa, Israel.

Erez Sharoni (E)

cardiothoracic surgery, Carmel Medical Center Cardiovascular Center, Haifa, Israel.

Classifications MeSH